



Preclinical Assessment Of Nitrogen-Containing Heterocyclic Derivatives For Breast Cancer Intervention In Animal Models

Samiksha Kurekar¹, Shrushti Tilekar², Sahil Javheri³, Tanmay Randhe⁴,
Yogesh Zambare^{5*}, Shankar Budhwani⁶, Vivek Panchbhai⁷, Pavan Chinchole⁸

^{1,2,3,4,5*} Krishnarao Bhegade Institute of Pharmaceutical Education & Research, Talegaon Dabhade, Tal. Maval, Dist. Pune 410507, Maharashtra, India.

⁶Genesis Institute of Pharmacy Radhanagari, Dist. Kolhapur 416212, Maharashtra, India.

⁷Channabasweshwar Pharmacy college, Kava road, Dist. Latur 413512, Maharashtra, India.

⁸Dr. Rajendra Gode College of Pharmacy, Malkapur, Dist. Amravati 444901, Maharashtra, India.

***Corresponding Author :-Dr. Yogesh Zambare**

*Krishnarao Bhegade Institute of Pharmaceutical Education & Research, Talegaon Dabhade, Tal. Maval, Dist. Pune 410507, India. Email : yogeshzambare.iiper@gmail.com

Abstract

Due to their inherent adaptability and distinctive physicochemical characteristics, the majority of heterocycle compounds and generally frequent heterocycle units found in the majority of medications now on the market have established them as genuine bases of medicinal chemistry. In addition to the medications that are now on the market, several more are being researched for their possible effectiveness in treating a variety of cancer. Specifically, these molecules inherent adaptability and dynamic core scaffold have been used in anticancer research. However, much like every other potential anticancer medication, heterocyclic compounds have drawbacks. We give a succinct summary of heterocyclic active compounds and families in this study, along with an emphasis on their primary medical uses. While examining the primary biochemical mechanisms of action, biological targets, structure-activity connections, and fundamental limitations in the utilisation of these substances, we have concentrate on those that are appropriate for cancer therapy.

CC License
CC-BY-NC-SA 4.0

INTRODUCTION

Breast cancer is the most common malignancy in women.(1) Breast carcinoma is the most frequently diagnosed carcinoma, followed by pulmonary carcinoma with 2.09 million cases.(2) Breast cancer is originates in breast tissue and they are most frequently arises from the cell surrounding lobuled and milk duct.(3)

Lobular carcinomas are the name for cancers that start in the lobules, while those originate in the ducts are called ductal carcinomas. an there are approximately 20+ different breast cancer types. (4) Due to current rises in incidence and repercussions on different mental, physical as well as social facets of human existence, cancer has emerged as a significant concern of the present.(5)

World Health Organisation (WHO) shows that, cancer is the third or fourth major reason for mortality in 22 countries before the age of 70 and the 1st and 2nd most common cause in of 180 nations. According to

GLOBOCAN 2020, In the twenty-first century, cancer is set to overtake all other causes of death as the main threat to increasing life expectancy throughout the world, and non-communicable diseases are now responsible for the majority of fatalities internationally. (6) The most recent statistics available from Iran's Cancer Research Centre indicates that 1400 out of the 8500 newly reported cases of breast cancer result in death per year. (7)

One in nine women will develop breast cancer over their lives.(8) Risk will raised when a person have a mother, sister or daughter who has breast cancer. But majority of people having breast cancer with no family history. The likelihood of breast cancer in men is significantly lower. Breast cancer affects one in 833 males on average, and age, genetics, obesity, alcohol use, and environmental factors appear to be the main risk factors (9).

The genes that cause breast cancer include Breast Cancer Gene 1 (BRCA1), Breast Cancer Gene 2 (BRCA2), Ataxia Telangiectasia Mutated (ATM), Human Epidermal Growth Factor Receptor 2 (HERS),and Epidermal Growth Factor Receptor (EGFR). (10) BRCA1 and BRCA2 are present in human's8 chromosome 17q21 and 13q12 respectively. BRCA1 an BRCA2 are negative regulators of cell division (anti-oncogenes). (11) HERS are present in chromosomes 17q12 and it is also called as c-erbB-2. It was initially discovered in neuroblastoma cells of rat. (12) EGFR are present in chromosomes 7p12 and it is also called as c-erbB-1. (13)

The Sixth Period in ancient Egypt has the earliest known proof of breast cancer, which goes 4200 years back. The examination of a female's bones from the Qubbet el-Hawa necropolis revealed the typical devastating devastation brought on by metastatic spread. (14)

The prominent screening technique to detect breast cancer is Mammography and some more screening techniques are Magnetic Resonance Imaging (MRI) etc. (15) There are different degrees to which cancer affects people's quality of life. Emotional consequences, mental health issues, depression, pain, therapeutic and diagnostic procedures, and social life all have a negative effect on patients life . (16)

Several medications have been granted support from the US-FDA for the treatment of breast-related cancers. Resistances frequently appear, thus new molecules are urgently required to address these issues. (17)

Finding novel applications for already available neoplastic medications in the treatment of breast cancer is increasingly crucial for creating better treatment plans and enhancing overall. (18)

NITROGEN CONTAINING HETEROCYCLIC RING –

By wide range of biological activities, heterocyclic compounds have made significant contributions to society in the form of several medications for the treatment of different diseases. They also have a major position in medicinal chemistry. (19)

1. QUINOLINE DERIVATIVES -

Quinoline is a heterocyclic, aromatic chemical that contains nitrogen as heteroatom obtained from Cinchona Alkaloids. A wide variety of biological activity can be seen by pharmacologically active compounds. (20)

Quinoline derivatives have a crucial role in medicine. It shows many activities like antifungal, antimalarial antibacterial, anti imflammatory, anticonvulsant. And quinoline molecule also used in the preparation of virucides, fungicides, biocites and many other. (21)

Some drugs are currently present in the market like belotecan, bosutinib, topotecan, cabozantinib, foretinib, irinotican,lenvatinib, niratinib and many more.(22)

2. INDOLE DERIVATIVE-

Indole C_8H_7N is a heterocyclic organic compound in which benzene ring is fused with pyrrole ring.(23) Indole is synthesized in the shikimate pathway from anthranilate.(24) Due to its remarkable pharmacological qualities, indole has been drawing researchers' interest and has emerged as a popular topic of research.(25) It is utilised in the discovery and design of target-based anticancer durgs.(26) And it also posses many other pharmacological activities like antimicrobial, antiviral, immflamatory etc.(27)

The indolemoeity is extensively prevalent in nature and it is found in a number of significant alkaloids, including tryptophan and auxins. (28) Treatments for several malignancies, including Hodgkin's disease, non-Hodgkin's, and prostate cancer, breast cancer involve the use of dimericmonoterpeneindole alkaloids such as vinblastine and vincristine. (29).

3. IMIDAZOLE DERIVATIVE-

It is an alkaloid that aids as a vital role in the search for new drugs. (30) And it can be obtained from various resources.(31) Imidazole is a compound present in many existing drugs and has many therapeutic

activities. And it also possess major role as anti- cancer activity.(32) Since imidazole was discovered in the 1840s by Heinrich Debus.(33)

The investigation and modification of imidazole-based compounds possess fascinating action. Imidazoles have a several biological effects, including anti-cancer, anti-inflammatory, anti-viral, antitubercular, antiparasitic, antineuropathic and many medicinal applications. (34) Imidazoles have been employed as potent anticancer agents among all other pharmacological uses. Several imidazoles, such as temzolomide, mercaptopurine, nilotinib, dacarbazine, are now utilised in clinics to treat a variety of malignancies. These compounds show remarkable pharmacological potential to treat cancer.(35)

4. CARBAZOLE DERIVATIVE-

Carbazole is aromatic heterocyclic compound which consists of two benzene rings fused with five member containing nitrogen as hetero atom. (36) The carbazole have been the basic structure of many therapeutically active molecules, which involves both natural and manufactured products, form more than 50 years amongst the available anti-cancer drugs.(37)

Most carbazole alkaloids come from higher plants belonging to the genus *Clausena*, *Murraya*, *Micromelum* all of which are members of the Rutaceae family. In addition, it is also obtained from fungus and bacteria.(38) They shows many pharmacological activities such as anticancer, anti-inflammatory, anti-oxidant, anti-psychotic, anti-bacterial, anti-diabetics.(39)

5. PYRIMIDINE DERIVATIVES-

Pyrimidine is aromatic organic compound in which nitrogen is at first position of a ring.(40) As "m-Diazine," a byproduct of the metabolism of uric acid, pyrimidines rose to prominence in the history of organic chemistry. Alloxan, the first pyrimidine derivative, was found by Brugna


telli in 1818.(41) The therapeutic effects of pyrimidine derivatives are well established in medicinal chemistry. Additionally, a number of pyrimidine derivatives have been created as chemotherapeutics. (42)

It has been reported that pyrimidine and its analogues have a great variety of biological potential, including anticancer,(43) antimicrobial, (44) antiviral (45), analgesic, (46) anti-inflammatory (47) etc.

SCHEMES


1. INDOLE -

Imran Ali *et. Al.* were synthesized novel indole based arylsulfonylhydrazides containing morpholine heterocyclic ring through multistep chemical reaction. And these compound was screened for there in vitro activity against estrogen receptor. (48)




In 2018, Bugaenko *et. al.* reported that the t-BuOK/DMF approach generated N-substituted indole-3-carboxylates substitutes in good yields.(49)


Khelifiet *al.* synthesised a unique series of isoCA-4 analogues to imitate the ability of isocombretastatin A-4 (isoCA-4) binds to the tubulin colchicine site to prevent polymerization by preventing the mitotic spindle from forming. And developing a range of novel isocombretastatin.



IsoCoQuines 2




In 2019, Swammy *et al.* suggested drugs that target EGFR. They created a set of 11 amide azindole-oxazole compounds and examined their anti-cancer properties using breast cancer cell lines. (51)




Cheng *et al.* concentrated on the synthesis of novel compounds in 2019 with the goal of developing HDAC inhibitors and anti-leukemic medicaments. They formed many indole substitute which combine with the inhibitory actions of HDAC and BRD4 into a single molecule by employing a structure forming design process.

They also shows to be the most potent inhibitor against HDAC3, with an IC₅₀ value of 5 nmol/L, and BRD4 with inhibition of 88% and rate at a dosage of 10 mol/L. (52)




2. QUINOLINE-


Azetidinone derivatives were created by K. Govindarao *et al.* (53) as potential antibreast cancer medicines that are effective against the cell lines MDA-MB-231 and MCF7. These result in high IC₅₀ values when compared to the typical human liver cell.




Mohamed Mokhtar and others (54) designed green synthesis of quinolinone derivatives which targets multi-receptor tyrosine kinases using the MCF-7 cell line. They utilized a copper nanoparticle catalyst that has been coated with chitosan under ultrasonic irradiation.



5-(Imidazolylmethyl)-2-Aryl-Quinoline analogues as Aromatase Inhibitors were reported by Ghodsi et al. in 1955. Quinolines 8a-g's toxicity to MCF-7 and T47D cell lines was evaluated.



Elbadawi *et al.* (56) synthesized α -alkoxytopoisomerase I which is inhibited by 2-aryl-6,7-dimethoxyquinolines derivative and halogen benzoyl chloride derivatives. And this activity is performed on mice cell line 4T1. And they found positive result against it.




7H Chromenoquinoline derivatives and 7,12-dihydrodibenzo naphthyridine were synthesised by R.A. Kardile *et al.* in 1957. They found dibenz naphthyridinone, indenoisoquinoline, indenoquinolone and indenoquinoline against C57MG cell line of mice. (57)


3. IMIDAZOLE DERIVATIVE-

Deryasmaniye and other (58) developed a derivatives of aromatase inhibitors. Here the thiazolyldiazone group inhibits MAO-B and theazole group binds to the HEM group of the enzyme to inhibit aromatase.


The main reason behind developing this combination was to minimize the negative effects of aromatase inhibitor caused by patient with breast cancer having lower oestrogen level while also preventing the effect of aromatase inhibitor on dopaminergic neurons.



M. shaheermaliket *Al.* (59) developed a novel N-phenylbenzamide derivatives, In order to understand binding affinity at the molecular level. The this derivative were then exposed to molecular docking. To gain a better understanding of the interactions at the receptor level, molecular dynamic simulations were also conducted. Additionally, computational research was done on the derivatives' molecular descriptors and drug-likeness characteristics.




Sara rahimzadehOskueiet *Al.*(60) develops a novel imidazole-chalcone derivatives which fight against cancer cells (MCF-7), and human hepatocellular carcinoma cells (HEPG2) and adenocarcinoma human alveolar basal epithelial cells (A549).




4. PYRIMDINE-

Behbehani *et al.* (2020) have developed a unique synthetic platform that employs a fresh, useful, and efficient method to generate considerably substituted pyridine systems. Making use of the MTT. The first cytotoxicity examination of these synthetic 10-pyridine derivatives was performed using a colorimetric test on human malignant cell lines, MCF-7 (breast cancer). All 10 of the pyridine derivatives showed considerable cytotoxic characteristics in experiments on malignant A549 and MCF-7 cells. The study's result indicates that the compounds indicated above might serve as appropriate main sources for upcoming research on the creation of anticancer medications. (61)



Onteddu Surendranatha and his associate have published a research detailing a productive method for the synthesis of 2,5-disubstituted pyrimidine. Suzuki produced the required 5-disubstituted pyrimidines by combining 2 substituted benzyloxy-5-bromopyrimidines with different aryl boronic acids in water at 80^o C WITH 0.5 M aq. In turn, 2-benzyloxy-5-eous Na₂CO₃. And a catalytic quality of PdCl₂(PPh₃)₂. Bromopyrimidines were produced via the reaction of substituted benzyl alcohols and 2-chloro-5-bromopyrimidine in CH₃CN:DMF (1:1) in the presence of Cs₂CO₃. A small number of 2,5-disubstituted pyrimidines have shown a modest degree of cytotoxicity in vitro against the HeLa cell line. (62)



R AN R1 : Aryl, hetroaryl

CONCLUSION:

Heterocycles appear to be involved in a number of metabolic biochemical processes in cells. Because of their reactivity with tissues and cells, these molecules regulation is so strictly regulated that any disruption may be linked to disease disorders. In order to upset the delicate equilibrium in cells, synthetic cyclic compounds used as anticancer medicines resemble natural ligands and substrates. Through boosting lipophilicity, polarity, or other physicochemical qualities, heterocyclic compounds or heterocyclic fragments also contribute significantly to improving the pharmacokinetics and pharmacodynamics aspects of anticancer

medicines. Because heterocycles are found in most marketed medications, they are therefore significant in today's drug design.

REFERENCE-

- McGuire A, Brown JA, Malone C, McLaughlin R, Kerin MJ. Effects of age on the detection and management of breast cancer. *Cancers*. 2015 May 22;7(2):908-29.
- Balasubramanian R, Rolph R, Morgan C, Hamed H. Genetics of breast cancer: management strategies and risk-reducing surgery. *British Journal of Hospital Medicine*. 2019 Dec 2;80(12):720-5.
- Elseaty A, Taktash M. Do Birth control pills increase the chance of getting breast cancer[?].
- World Cancer Report 2014*. World Health Organization. 2014. pp. Chapter 5.2. ISBN 978-92-832-0429-9.
- Poorkiani M, Hazrati M, Abbaszadeh A, Jafari P, Sadeghi M, Dejbakhsh T, Panah MM. Does a rehabilitation program improve quality of life in breast cancer patients?. *Payesh (Health Monitor)*. 2010 Jan 15;9(1):61-8.
- Bray FF, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal AJ. Erratum: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *Ca Cancer J Clin*. 2020;70(4):313.
- Zoya T, Mitra M, Behzad M. Breast Cancer: A preventable disease
- Sohail S, Alam SN. Breast cancer in Pakistan-awareness and early detection.
- Chen F, Zhou J, Xue Y, Yang S, Xiong M, Li Y, Liu Q. A single nucleotide polymorphism of the TNRC9 gene associated with breast cancer risk in Chinese Han women. *Genet Mol Res*. 2014 Jan 10;13(1):182-7.
- Walsh T, King MC. Ten genes for inherited breast cancer. *Cancer cell*. 2007 Feb 13;11(2):103-5.
- Deng CX. BRCA1: cell cycle checkpoint, genetic instability, DNA damage response and cancer evolution. *Nucleic acids research*. 2006 Jan 1;34(5):1416-26.
- Shih C, Padhy LC, Murray M, Weinberg RA. Transforming genes of carcinomas and neuroblastomas introduced into mouse fibroblasts. *Nature*. 1981 Mar 19;290(5803):261-4.
- Appert-Collin A, Hubert P, Crémel G, Bennisroune A. Role of ErbB receptors in cancer cell migration and invasion. *Frontiers in pharmacology*. 2015 Nov 24;6:283.
- Mourad M, Stonestreet J. Oldest evidence of breast cancer found in Egyptian skeleton.
- Drukteinis JS, Mooney BP, Flowers CI, Gatenby RA. Beyond mammography: new frontiers in breast cancer screening. *The American journal of medicine*. 2013 Jun 1;126(6):472-9.
- Aggarwal SS. Breast cancer a major causing Cancer in women's. *International Journal of Cell Biology and Cellular Processes*. 2022 May 10;8(1):1-3.
- Ayana R, Vijayakumar B, Athulya P, Anjana VS, Vismaya KV, Swarnalatha G. A short review on heterocyclic compounds showing anti-breast cancer activity. *Journal of Scientific Research*. 2021 Sep 1;13(3):1075-98.
- Saroja T, Ezhilarasi RM, Selvamani V, Mahalakshmi S. Synthesis, characterization and in-silico analysis of new 2-pyrazolines. *Journal of Scientific Research*. 2021 Jan 1;13(1):183-94.
- Mulwad VV, Langi BP, Chaskar AC. Synthesis of novel biologically active heterocyclic compounds from 2-oxo-2H-benzopyran-6-yl-imidazolidine. *Acta Pol Pharm*. 2011 Jan 1;68(1):39-47.
- Allen JG, Galloway DB, Ehsanullah RS, Ruane RJ, Bird HA. The effect of bromazepam (Lexotan) administration on antipyrine pharmacokinetics in humans. *Xenobiotica*. 1984 Jan 1;14(4):321-6.
- A Al-Qawasmeh R, B Huthail B, O Sinnokrot M, H Semreen M, A Odeh R, H Abu-Zarga M, Tarazi H, A Yousef I, H Al-Tel T. Design, synthesis and qualitative structure activity relationship evaluations of quinoline-based bisarylimidazoles as antibacterial motifs. *Medicinal Chemistry*. 2016 Sep 1;12(6):563-73.
- Musiol R, Magdziarz T, Kurczyk A. Quinoline scaffold as a privileged substructure in antimicrobial drugs. *Science against microbial pathogens: communicating current research and technological advances*. 2011;1:72-83.
- Lee JH, Lee J. Indole as an intercellular signal in microbial communities. *FEMS microbiology reviews*. 2010 Jul 1;34(4):426-44.
- Nelson, David L.; Cox, Michael M. (2005). *Principles of Biochemistry* (4th ed.). New York: W. H. Freeman. ISBN 0-7167-4339-6
- Zhang MZ, Chen Q, Yang GF. A review on recent developments of indole-containing antiviral agents. *European journal of medicinal chemistry*. 2015 Jan 7;89:421-41.

26. Verma S, S Prabhakar Y. Target based drug design-a reality in virtual sphere. *Current medicinal chemistry*. 2015 Apr 1;22(13):1603-30.
27. Gul W, Hamann MT. Indole alkaloid marine natural products: An established source of cancer drug leads with considerable promise for the control of parasitic, neurological and other diseases. *Life sciences*. 2005 Dec 22;78(5):442-53.
28. Zhang MZ, Mulholland N, Beattie D, Irwin D, Gu YC, Chen Q, Yang GF, Clough J. Synthesis and antifungal activity of 3-(1, 3, 4-oxadiazol-5-yl)-indoles and 3-(1, 3, 4-oxadiazol-5-yl) methyl-indoles. *European journal of medicinal chemistry*. 2013 May 1;63:22-32
29. Ishikawa H, Colby DA, Boger DL. Direct coupling of catharanthine and vindoline to provide vinblastine: total synthesis of (+)-and ent(-)-vinblastine. *Journal of the American Chemical Society*. 2008 Jan 16;130(2):420-1.
30. Katritzky AR, Ramsden CA, Scriven EF, Taylor RJ. *Comprehensive heterocyclic chemistry III*. In V1 3-memb. Heterocycl., together with all Fused Syst. contain. a 3-memb. Heterocycl. Ring. V2 4-memb. Heterocycl. together with all Fused Syst. contain. a 4-memb. Heterocycl. Ring. V3 Five-memb. Rings with One Heteroat. together with their Benzo and other Carbocycl.-fused Deriv. V4 Five-memb. Rings with Two Heteroat., each with their Fused Carbocycl. Deriv. 2008 Jan 1 (pp. 1-13718).
31. Lo YS, Nolan JC, Maren TH, Welstead Jr WJ, Gripshover DF, Shamblee DA. Synthesis and physicochemical properties of sulfamate derivatives as topical antiglaucoma agents. *Journal of medicinal chemistry*. 1992 Dec;35(26):4790-4.
32. Foye WO. *Foye's principles of medicinal chemistry*. Lippincott williams&wilkins; 2008.
33. Hengel M, Shibamoto T. Carcinogenic 4 (5)-methylimidazole found in beverages, sauces, and caramel colors: chemical properties, analysis, and biological activities. *Journal of agricultural and food chemistry*. 2013 Jan 30;61(4):780-9.
34. Flatt PM, Gautschi JT, Thacker RW, Musafija-Girt M, Crews P, Gerwick WH. Identification of the cellular site of polychlorinated peptide biosynthesis in the marine sponge *Dysidea* (Lamellodysidea) herbacea and symbiotic cyanobacterium *Oscillatoriaspongelliae* by CARD-FISH analysis. *Marine Biology*. 2005 Jul;147:761-74.
35. Zhan P, Liu X, Zhu J, Fang Z, Li Z, Pannecouque C, De Clercq E. Synthesis and biological evaluation of imidazole thioacetanilides as novel non-nucleoside HIV-1 reverse transcriptase inhibitors. *Bioorganic & medicinal chemistry*. 2009 Aug 15;17(16):5775-81.
36. Favre HA, Powell WH. *Nomenclature of organic chemistry: IUPAC recommendations and preferred names 2013*. Royal Society of Chemistry; 2013 Dec 5.
37. Schmidt AW, Reddy KR, Knölker HJ. Occurrence, biogenesis, and synthesis of biologically active carbazole alkaloids. *Chemical reviews*. 2012 Jun 13;112(6):3193-328.
38. Chakraborty DP, Krohn K, Messner P, Roy S, Schäffer C, Chakraborty DP, Roy S. Carbazole alkaloids IV. *Fortschritte der Chemieorganischer Naturstoffe/Progress in the Chemistry of Organic Natural Products*. 2003:125-230.
39. Bashir M, Bano A, Ijaz AS, Chaudhary BA. Recent developments and biological activities of N-substituted carbazole derivatives: a review. *Molecules*. 2015 Jul 23;20(8):13496-517.
40. Joule JA. *Heterocyclic chemistry*. CRC Press; 2020 Nov 25.
41. Lagoja IM. Pyrimidine as constituent of natural biologically active compounds. *Chemistry & Biodiversity*. 2005 Jan;2(1):1-50.
42. Basha J, Goudgaon NM. A comprehensive review on pyrimidine analogs-versatile scaffold with medicinal and biological potential. *Journal of Molecular Structure*. 2021 Dec 15;1246:131168.
43. Cocco MT, Congiu C, Onnis V, Piras R. Synthesis and antitumor evaluation of 6-thioxo-, 6-oxo- and 2, 4-dioxypyrimidine derivatives. *IIFarmaco*. 2001 Sep 1;56(10):741-8.
44. Anupama B, Dinda SC, Prasad YR, Rao AV. Synthesis and antimicrobial activity of some new 2, 4, 6-trisubstituted pyrimidines. *Int J Res Pharm Chem*. 2012;2(2):231-6.
45. Meneghesso S, Vanderlinden E, Stevaert A, McGuigan C, Balzarini J, Naesens L. Synthesis and biological evaluation of pyrimidine nucleoside monophosphate prodrugs targeted against influenza virus. *Antiviral research*. 2012 Apr 1;94(1):35-43.
46. Ashour HM, Shaaban OG, Rizk OH, El-Ashmawy IM. Synthesis and biological evaluation of thieno [2', 3': 4, 5] pyrimido [1, 2-b][1, 2, 4] triazines and thieno [2, 3-d][1, 2, 4] triazolo [1, 5-a] pyrimidines as anti-inflammatory and analgesic agents. *European Journal of Medicinal Chemistry*. 2013 Apr 1;62:341-51.
47. Tozkoparan B, Ertan M, Kelicen P, Demirdamar R. Synthesis and anti-inflammatory activities of some thiazolo [3, 2-a] pyrimidine derivatives. *IIFarmaco*. 1999 Sep 30;54(9):588-93.

48. Rivera NR, Balsells J, Hansen KB. Synthesis of 2-amino-5-substituted-1, 3, 4-oxadiazoles using 1, 3-dibromo-5, 5-dimethylhydantoin as oxidant. *Tetrahedron letters*. 2006 Jul 12;47(28):4889-91.
49. Bugaenko DI, Dubrovina AA, Yurovskaya MA, Karchava AV. Synthesis of indoles via electron-catalyzed intramolecular C–N bond formation. *Organic Letters*. 2018 Nov 15;20(23):7358-62.
50. Khelifi I, Naret T, Renko D, Hamze A, Bernadat G, Bignon J, Lenoir C, Dubois J, Brion JD, Provot O, Alami M. Design, synthesis and anticancer properties of IsoCombretaQuinolines as potent tubulin assembly inhibitors. *European journal of medicinal chemistry*. 2017 Feb 15;127:1025-34.
51. VenkatSwamy P, Kiran Kumar V, RadhakrishnamRaju R, Venkata Reddy R, Chatterjee A, Kiran G, Sridhar G. Amide derivatives of 4-azaindole: Design, synthesis, and EGFR targeting anticancer agents. *Synthetic Communications*. 2020 Jan 2;50(1):71-84.
52. Cheng G, Wang Z, Yang J, Bao Y, Xu Q, Zhao L, Liu D. Design, synthesis and biological evaluation of novel indole derivatives as potential HDAC/BRD4 dual inhibitors and anti-leukemia agents. *Bioorganic Chemistry*. 2019 Mar 1;84:410-7.
53. Govindarao K, Srinivasan N, Suresh R, Raheja RK, Annadurai S, Bhandare RR, Shaik AB. Quinoline conjugated 2-azetidinone derivatives as prospective anti-breast cancer agents: In vitro antiproliferative and anti-EGFR activities, molecular docking and in-silico drug likeliness studies. *Journal of Saudi Chemical Society*. 2022 May 1;26(3):101471.
54. Mokhtar M, Alghamdi KS, Ahmed NS, Bakhotmah D, Saleh TS. Design and green synthesis of novel quinolinone derivatives of potential anti-breast cancer activity against MCF-7 cell line targeting multi-receptor tyrosine kinases. *Journal of Enzyme Inhibition and Medicinal Chemistry*. 2021 Jan 1;36(1):1453-70.
55. Ghodsi R, Azizi E, GraziaFerlin M, Pezzi V, Zarghi A. Design, synthesis and biological evaluation of 4-(imidazolylmethyl)-2-aryl-quinoline derivatives as aromatase inhibitors and anti-breast cancer agents. *Letters in Drug Design & Discovery*. 2016 Jan 1;13(1):89-97.
56. Elbadawi MM, Eldehna WM, Wang W, Agama KK, Pommier Y, Abe M. Discovery of 4-alkoxy-2-aryl-6, 7-dimethoxyquinolines as a new class of topoisomerase I inhibitors endowed with potent in vitro anticancer activity. *European journal of medicinal chemistry*. 2021 Apr 5;215:113261.
57. Kardile RA, Sarkate AP, Borude AS, Mane RS, Lokwani DK, Tiwari SV, Azad R, Burra PV, Thopate SR. Design and synthesis of novel conformationally constrained 7, 12-dihydrodibenzo [b, h][1, 6] naphthyridine and 7H-Chromeno [3, 2-c] quinoline derivatives as topoisomerase I inhibitors: In vitro screening, molecular docking and ADME predictions. *Bioorganic Chemistry*. 2021 Oct 1;115:105174.
58. Osmaniye D, Levent S, Sağlık BN, Karaduman AB, Özkay Y, Kaplancıklı ZA. Novel imidazole derivatives as potential aromatase and monoamine oxidase-B inhibitors against breast cancer. *New Journal of Chemistry*. 2022;46(16):7442-51.
59. Malik MS, Alsantali RI, Jamal QM, Seddigi ZS, Morad M, Alsharif MA, Hussein EM, Jassas RS, Al-Rooqi MM, Abduljaleel Z, Babalgith AO. New imidazole-based N-phenylbenzamide derivatives as potential anticancer agents: Key computational insights. *Frontiers in Chemistry*. 2022 Jan 19;9:808556.
60. Oskuei SR, Mirzaei S, Jafari-Nik MR, Hadizadeh F, Eisvand F, Mosaffa F, Osk R. Design, synthesis and biological evaluation of novel imidazole-chalcone derivatives as potential anticancer agents and tubulin polymerization inhibitors. *Bioorganic Chemistry*. 2021 Jul 1;112:104904.
61. Behbehani H, Aryan FA, Dawood KM, Ibrahim HM. High pressure assisted synthetic approach for novel 6, 7-dihydro-5 H-benzo [6, 7] cyclohepta [1, 2-b] pyridine and 5, 6-dihydrobenzo [h] quinoline derivatives and their assessment as anticancer agents. *Scientific Reports*. 2020 Dec 10;10(1):21691.
62. Reddy OS, Suryanarayana CV, Narayana KJ, Anuradha V, Babu BH. Synthesis and cytotoxic evaluation for some new 2, 5-disubstituted pyrimidine derivatives for anticancer activity. *Medicinal Chemistry Research*. 2015 May;24:1777-88.